821 results on '"Targownik, Laura E."'
Search Results
2. Considerations in gender-affirming hormone therapy in transgender and gender diverse patients undergoing liver transplantation
3. Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies
4. Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn’s Disease but Not in Ulcerative Colitis
5. The association of efficacy, optimism, uncertainty and health anxiety with inflammatory bowel disease activity
6. Outcomes of patients admitted with acute, severe ulcerative colitis on biologic therapy: a retrospective analysis from a tertiary referral hospital.
7. Approaching Digestive Health Care in Transgender and Gender-Diverse Communities
8. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study
9. Hospitalization with Clostridioides difficile in pediatric inflammatory bowel disease: a population-based study
10. Anxiety and Depression Leads to Anti–Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease
11. What Is a Flare? The Manitoba Living With IBD Study
12. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
13. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data
14. Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study
15. LGBTQ+ Considerations in pediatric IBD care.
16. Hormonal Contraceptives Reduce Active Symptomatic Disease but May Increase Intestinal Inflammation in IBD.
17. Variation in the Care of Children with Inflammatory Bowel Disease Within and Across Canadian Provinces: A Multi-Province Population-Based Cohort Study.
18. S989 Outcomes of Patients Admitted With Acute, Severe Ulcerative Colitis on Established Biologic Therapy: A Retrospective Analysis from a Tertiary Referral Hospital
19. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
20. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD
21. The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease
22. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—Children and Adolescents with IBD
23. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors
24. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care
25. The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD
26. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs
27. Research Considerations in Digestive and Liver Disease in Transgender and Gender-Diverse Populations
28. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
29. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs
30. The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease
31. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery
32. The Economics of Inflammatory Bowel Disease
33. Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study
34. Utility of the MARS-5 in Assessing Medication Adherence in IBD
35. The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events
36. Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study
37. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary
38. Workplace Accommodation for Persons With IBD: What Is Needed and What Is Accessed
39. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis
40. Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse
41. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD
42. Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study
43. Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study
44. Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD
45. Hormonal Contraceptives Reduce Active Symptomatic Disease but May Increase Intestinal Inflammation in IBD
46. Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study
47. Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease
48. Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis
49. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease
50. Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.